

PRESS RELEASE – FOR IMMEDIATE DISTRIBUTION

## IntegraGen Reports 2017 revenue and cash position

- **2017 Revenue: +4% to €6.2 million**
- **Significant increase in clinical genomics business: + 14%**
- **Increased in orders booked for genomics services business: + 12%**
- **Launch of commercial activities for diagnostics business: first licensing agreement for miR-31-3p signed with Laboratoire CERBA and successful IVD CE marking of the miRpredX 31-3p diagnostic kit obtained in September.**
- **Cash position at the end of December 2017: €4.1 million**

### 2018 Outlook

- **Commercial launch of genomic data interpretation software (exome and transcriptome)**
- **Revenue ramp for miRpredX kit, test predicts response to anti-EGFR treatment for patients with metastatic colorectal cancer**

**ÉVRY, France (January 9, 2018)** - IntegraGen, a company specializing in the decoding of the human genome with a focus on producing interpretable genomic analyzes for academic and private laboratories and developing diagnostic tools in oncology, today announces its unaudited sales revenue for the 2017.

<i>In millions of euros</i>	<b>2017</b>	2016	<b>% Increase</b>
<b>Sales revenue</b>	<b>6,247</b>	6,022	<b>+4%</b>
	<b>December 31, 2017</b>	December 31, 2016	
<b>Cash position (in millions of euros)</b>	<b>4,138</b>	2,727	

2017 annual sales revenue increased 4% compared to 2016. The clinical segment of the company’s genomic services business experienced an 14% in sales revenue for the year primarily as a result of a significant increase in the number of clinical research projects carried out in collaboration with the Gustave Roussy cancer center. In the R & D segment, revenue was down slightly (4%) in value while the number of orders booked recorded a sharp increase (12%). In the diagnostics business, the company recorded its first income with 140K € in sales related to the contract with Laboratoire Cerba signed in March 2017. The miRpredX 31-3p kit obtained IVD CE mark in September 2017 and is now available on the market. This test enables clinicians to predict the response to anti-EGFR treatments for patients with metastatic colorectal cancer.

The company also announces the release of genomic data interpretation software in 2018. This tool will enable clinicians to refer patients with cancer to appropriate innovative therapeutic strategies (particularly in the context of new molecules in phase I or II clinical trial) where there is a higher probability of clinical treatment success, given the specific genomic characteristics of a patient's tumor.

At the end of December 2017, the company's cash balance was € 4.1 million compared to € 2.7 million at December 31, 2016. The company successfully completed a € 3.7m capital increase in February 2017.

Bernard Courtieu, IntegraGen's Chief Executive Officer, stated "IntegraGen closed 2017 with a further increase in sales during a year that also marked the launch of a diagnostic test that significantly improves the management of patients with colorectal cancer. The project we launched in 2016 to manufacture a kit for the miR-31-3p test, enabled us to obtain IVD CE marking in the second half of the 2017. Significant milestones await us in 2018, including the commercial launch of our sequencing data interpretation software. Planned projects for 2018, a full order book and a comfortable cash flow enable us to start this year 2018 with optimism and ambition."

## About IntegraGen

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2016, IntegraGen had 38 employees and had generated revenue of €6.0 million in 2016. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit [www.integragen.com](http://www.integragen.com)



## CONTACTS

### IntegraGen

Bernard COURTIEU  
President and CEO

Laurence RIOT LAMOTTE  
Chief Financial Officer  
[contact@integragen.com](mailto:contact@integragen.com)  
Tel.: +33 (0)1 60 91 09 00

### NewCap

Investor and Media Relations  
Louis-Victor DELOUVRIER  
[integragen@newcap.eu](mailto:integragen@newcap.eu)  
Tel.: +33 (0)1 44 71 98 53